Combined treatment using adoptive cell therapy, extended pharmacokinetic IL-2, and tumor-specific antibodies leads to cures of established B16F10 tumors and extended in vivo T cell survival

Lignende værker

• Adoptive cell therapy with tumor infiltrating lymphocytes and intermediate dose IL-2 for metastatic melanoma
  af: Andersen, Rikke, et al.
  Udgivet: (2014)
• Synergistic innate and adaptive immune response to combination immunotherapy with anti-tumor antigen antibodies and extended serum half-life IL-2
  af: Zhu, Eric F., et al.
  Udgivet: (2015)
• Anti-tumor antibodies can drive therapeutic T cell responses
  af: Wittrup, K. Dane
  Udgivet: (2017)
• IL-2, IL-15 and IL-21 expand T cells for targeted adoptive therapy
  af: Liu, Zhenjiang, et al.
  Udgivet: (2015)
• Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells
  Udgivet: (1982)